Robaxin: Targeted Muscle Relaxation for Acute Musculoskeletal Pain
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.44 | $34.40 (0%) | 🛒 Add to cart |
| 20 | $1.94 | $68.80 $38.70 (44%) | 🛒 Add to cart |
| 30 | $1.43 | $103.20 $43.00 (58%) | 🛒 Add to cart |
| 60 | $0.79 | $206.40 $47.30 (77%) | 🛒 Add to cart |
| 90 | $0.57 | $309.60 $51.60 (83%) | 🛒 Add to cart |
| 120 | $0.50 | $412.80 $60.20 (85%) | 🛒 Add to cart |
| 180 | $0.43 | $619.20 $77.40 (88%) | 🛒 Add to cart |
| 270 | $0.38 | $928.80 $103.20 (89%) | 🛒 Add to cart |
| 360 | $0.36
Best per pill | $1238.40 $129.00 (90%) | 🛒 Add to cart |
Synonyms | |||
Robaxin (methocarbamol) is a centrally acting skeletal muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is used as an adjunct to rest, physical therapy, and other measures for the symptomatic management of these conditions. The medication works by depressing polysynaptic spinal reflexes and inhibiting the transmission of neuronal impulses, thereby reducing skeletal muscle hyperactivity without directly affecting muscle contractility. Its clinical utility lies in providing symptomatic relief while the underlying musculoskeletal pathology is addressed through primary therapeutic interventions.
Features
- Active ingredient: Methocarbamol
- Available in 500mg and 750mg oral tablets
- Also available in injectable form for hospital use
- Onset of action: Typically within 30 minutes of administration
- Plasma half-life: Approximately 1-2 hours
- Metabolized hepatically via dealkylation and hydroxylation
- Excreted primarily renally (as metabolites and unchanged drug)
Benefits
- Provides rapid relief from acute muscle spasms and associated pain
- Reduces skeletal muscle hyperactivity without impairing normal muscle function
- Facilitates participation in physical therapy and rehabilitation programs
- Helps restore range of motion and functional capacity
- May reduce the need for higher doses of adjunct analgesic medications
- Supports recovery from acute musculoskeletal injuries
Common use
Robaxin is commonly prescribed for the management of acute musculoskeletal conditions characterized by muscle spasm and pain. These include but are not limited to: acute low back pain with muscle spasm, cervical strain syndromes, post-traumatic muscle injuries, postoperative pain management involving muscular components, and certain neurological conditions causing muscle hypertonicity. It is typically used for short-term management (usually 2-3 weeks) as part of a comprehensive treatment approach that includes physical modalities, appropriate exercise, and other pain management strategies.
Dosage and direction
The recommended adult dosage for Robaxin tablets is 1500mg four times daily for the first 48-72 hours of treatment (up to 8g per day in severe conditions). For maintenance therapy, the dosage may be reduced to 4000-4500mg daily divided into three or four doses. The tablets should be taken with a full glass of water and may be administered with food to minimize potential gastrointestinal discomfort. Treatment duration should not exceed three weeks unless specifically directed by a healthcare provider, as the benefit-risk ratio for longer-term use has not been established. Dosage adjustment is recommended in patients with hepatic impairment.
Precautions
Patients should be advised that Robaxin may cause drowsiness, dizziness, or blurred vision. Activities requiring mental alertness, such as operating machinery or driving, should be avoided until the individual’s response to the medication is known. Concurrent use with other central nervous system depressants (including alcohol) may enhance these effects. Caution is advised in patients with a history of drug abuse or dependence. Hepatic function should be monitored during prolonged therapy. The medication contains FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions in susceptible individuals.
Contraindications
Robaxin is contraindicated in patients with known hypersensitivity to methocarbamol or any component of the formulation. It should not be used in patients with renal impairment severe enough to potentially affect drug elimination. The injectable form is contraindicated in patients with epilepsy or other seizure disorders. Use during pregnancy should be avoided unless the potential benefit justifies the potential risk to the fetus, as adequate human studies are lacking. The drug is not recommended for use in children under 16 years of age due to insufficient safety data.
Possible side effects
The most commonly reported adverse reactions include dizziness, drowsiness, nausea, and headache. Less frequent side effects may include blurred vision, fever, allergic manifestations, and gastrointestinal disturbances. Rare but serious adverse effects include anaphylactic reactions, leukopenia, and cholestatic jaundice. The injectable formulation may cause pain at the injection site, flushing, metallic taste, and hypotension. Patients should be monitored for any signs of hypersensitivity reactions, particularly during initial administration.
Drug interaction
Robaxin may potentiate the effects of other CNS depressants including alcohol, benzodiazepines, opioids, sedative antihistamines, and tricyclic antidepressants. Concurrent use with MAO inhibitors may enhance adverse effects. The drug may interfere with laboratory tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Caution is advised when administering with drugs that affect hepatic metabolism, as methocarbamol is metabolized by the liver.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one, as this may increase the risk of adverse effects.
Overdose
Symptoms of overdose may include nausea, vomiting, drowsiness, blurred vision, hypotension, seizures, and coma. Management involves gastric lavage if presentation is early, followed by supportive care including maintenance of adequate respiratory function and cardiovascular support. There is no specific antidote for methocarbamol overdose. Hemodialysis may be considered in severe cases, though its efficacy has not been established.
Storage
Robaxin tablets should be stored at controlled room temperature (20-25°C or 68-77°F) in a tightly closed container, protected from light and moisture. The medication should be kept out of reach of children and pets. Unused medication should be properly disposed of according to local regulations and should not be flushed down the toilet or poured into drains unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. The prescribing information contained herein is not exhaustive. Patients should consult with a qualified healthcare professional before starting, stopping, or changing any medical treatment. The manufacturer’s official prescribing information should be consulted for complete details regarding administration, contraindications, and warnings.
Reviews
Clinical studies have demonstrated Robaxin’s efficacy in managing acute musculoskeletal pain. In randomized controlled trials, patients receiving methocarbamol showed significant improvement in muscle spasm and pain scores compared to placebo. Many practitioners report satisfactory results when used appropriately as part of a comprehensive treatment plan. Patient satisfaction surveys indicate improved functional outcomes and reduced pain interference with daily activities. However, some reviews note that the sedative effects may be limiting for certain patients, and individual response can vary considerably.